Largest study of its kind reveals surprising outcome for people who receive COVID vaccine

People who received at least one dose of the Covid vaccine may live longer than those who didn't get the shot, a major study ...

Winter virus season so far is not too bad, but doctors worry about suffering to come

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Bristol-Myers Squibb (NYSE:BMY), BioNTech (NASDAQ:BNTX)

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...
TipRanks on MSN

BioNTech and OncoC4 report positive phase 3 trial results for Gotistobart in lung cancer

BioNTech SE ( ($BNTX) ) has provided an update. On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal ...

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...